-Cathryn Rankin Researcher Activity Profile

Research Author Detailed Information 

Cathryn Rankin Publication Rate By Year

Cathryn Rankin has published 1 paper(s) in 2003, 4 paper(s) in 2007, 3 paper(s) in 2008, for a total of 8 research publications in total.

Cathryn C Rankin Author Information

LAST NAME: rankin

FIRST NAME: cathryn

INITIALS: C

AFFILIATION:

Papers

Cathryn Rankin's Publication Record

1. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. Year Published: 2007
University of Arizona Cancer Center, Tucson, AZ, USA.
2. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). Year Published: 2007
Division of Medical Oncology, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium, Seattle, Washington.
3. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Year Published: 2007
Division of Medical Oncology, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium, Seattle, Washington 98109, USA. spetersd@u.washington.edu
4. A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). Year Published: 2008
Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, CRB 2M88, 1650 Orleans Street, Baltimore, MD, 21231, USA, lswinne1@jhmi.edu.
5. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Year Published: 2007
Division of Medical Oncology, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium, Seattle, Washington 98109, USA. spetersd@u.washington.edu
6. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Year Published: 2008
Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L-586, Portland, OR 97239, USA. blankec@ohsu.edu
7. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Year Published: 2008
Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L-586, Portland, OR 97239, USA. blankec@ohsu.edu
8. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Year Published: 2003
Division of Medical Oncology, Columbia University, College of Physicians and Surgeons, New York, New York, USA.